First Wave BioPharma Changes Name to Entero Therapeutics, Company Advances Toward Phase 3 Clinical Trial With Lead Asset – Latiglutenase For The Treatment Of Celiac Disease
Portfolio Pulse from Benzinga Newsdesk
First Wave BioPharma has rebranded to Entero Therapeutics and is advancing towards a Phase 3 clinical trial for its lead asset, Latiglutenase, aimed at treating celiac disease. The company's stock will trade under the new ticker symbol ENTO starting May 17, 2024.
May 16, 2024 | 11:30 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Entero Therapeutics, formerly First Wave BioPharma, is advancing towards a Phase 3 clinical trial for Latiglutenase, targeting celiac disease. The rebranding and new ticker symbol (ENTO) will take effect on May 17, 2024.
The rebranding and advancement towards a Phase 3 clinical trial for a treatment targeting an unmet medical need (celiac disease) are positive developments. The new ticker symbol and focus on GI diseases could attract investor interest.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100